Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 7/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20559817 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20559410 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20558932 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20559411 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20559415 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20559409 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20559820 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20558929 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL20799654 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 | |
| SCHEMBL19146676 | 1.00 | HTR2B (0.41) | HTR2BHPGDLPAR2TP53HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | HTR2B 967/4885HPGD 3512/4885LPAR2 2467/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | HTR2B 878/4885HPGD 3843/4885LPAR2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.